English
Regional settings| Spread | 0.0344 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 0.01 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 1.9428 |
| Open | 1.9428 |
| 1-Year Change | -38.91% |
| Day's Range | 1.9428 - 1.9428 |
Aeterna Zentaris Inc. (AEZS) is a biopharmaceutical company headquartered in Summerville, South Carolina.
Founded in 1990, the company specialises in diagnostics, therapeutics and Salmonella-based vaccine platforms. Its diagnostic drug, Macimorelin, for adult growth hormone deficiency (AGHD) is currently in the commercial phase. Macimorelin designed for childhood-onset growth hormone deficiency (CGHD) is in Phase 3 clinical trials.
The portfolio of therapeutic drugs includes AIM Biologicals for neuromyelitis optica spectrum disorder and Parkinson’s disease, Macimorelin for amyotrophic lateral sclerosis (ALS) and AEZS-150 for chronic hypoparathyroidism, all in the pre-clinical phase.
The vaccine programme is engaged in the development of vaccines for Covid-19 and Chlamydia trachomatis, both are in the pre-clinical trial.
Aeterna Zentaris leverages its network of large pharma and university partners and collaborators to develop and commercialise drugs faster. A licence agreement with the University of Wuerzburg is enabling the pharmaceutical company to develop the Covid-19 vaccine, treatment for neuromyelitis optica spectrum disorder and Parkinson's disease (preclinical phase); and 3D human intestinal tissue models to study infection.
Aeterna Zentaris has a development and commercialisation agreement for macimorelin with Novo Nordisk (NVO) and NK MEDITECH Ltd. It has an exclusive licence agreement with the University of Queensland, Australia for the investigation of macimorelin as a potential treatment for ALS.
The company went public in 2000, listing on the NASDAQ. Aeterna Zentaris stock trades under the ticker symbol AEZS.
You can follow the Aeterna Zentaris share value and price movement live through AEZS stock price chart at Capital.com.
